Home / Innere Medizin / Onkologie / ASCO 2019: Scientific Knowledge Exchange on Immunotherapy in Melanoma

ASCO 2019: Scientific Knowledge Exchange on Immunotherapy in Melanoma

In this year’s Scientific Knowledge Exchange, Prof. Dr. Reinhard Dummer, University Hospital of Zurich, and Prof. Dr. Olivier Michielin, University Hospital of Lausanne, discuss ASCO 2019’s news in melanoma research and therapy.

Source: ASCO 2019

The following abstracts are discussed in this SKE:

#9511 Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy. https://meetinglibrary.asco.org/record/174187/abstract

#100 Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.
https://meetinglibrary.asco.org/record/174917/abstract

#9501 Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). https://meetinglibrary.asco.org/record/173427/abstract

#9500 Fogarty G et al. Phase 3 international trial of adjuvant whole brain radiotherapy (WBRT) or observation (Obs) following local treatment of 1-3 melanoma brain metastases (MBMs). http://meetinglibrary.asco.org/content/258029-239

#9551 Patient-reported quality of life (QoL) of advanced melanoma patients in a Phase 3 study of nivolumab (NIVO) with or without ipilimumab (IPI) versus IPI: CheckMate 067 4-year data. https://meetinglibrary.asco.org/record/176201/abstract

#9531 The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i.
https://meetinglibrary.asco.org/record/174904/abstract

#9502 Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: Updated results from a phase III trial (CheckMate 238). https://meetinglibrary.asco.org/record/159076/abstract

#9520 One-year (yr) recurrence-free survival (RFS) from a randomized, open label phase II study of neoadjuvant (neo) talimogene laherparepvec (T-VEC) plus surgery (surgx) versus surgx for resectable stage IIIB-IVM1a melanoma (MEL).
https://meetinglibrary.asco.org/record/174628/abstract

#9503 Pathological response and survival with neoadjuvant therapy in melanoma: A pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). https://meetinglibrary.asco.org/record/173444/abstract

#9509 Phase 1 study of MK-4166, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody, as monotherapy or with pembrolizumab (pembro) in patients (pts) with advanced solid tumors.
https://meetinglibrary.asco.org/record/173429/abstract

9522# Phase II study of ipilimumab and nivolumab (ipi/nivo) in metastatic uveal melanoma (UM).
https://meetinglibrary.asco.org/record/174882/abstract

#9505 Salvage therapy after failure from anti-PD-1 single agent treatment: A Study by the German ADOReg melanoma registry.
https://meetinglibrary.asco.org/record/174824/abstract

LOGIN

Login

Passwort vergessen?